

Ovarian Cancer (Epithelial) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: _____

ICD-10 Code: _____

Biomarkers/Characteristics: (Select all that apply)

Paclitaxel-resistant: __Yes __No

Platinum Sensitive*: __Yes __No __Not Reported

Platinum Refractory/Resistant: __Yes __No __Not Reported

Adjuvant Therapy

- Stages IA/IB (Grade 2 or 3), and IC (Grade 1-3)
 - Carboplatin and paclitaxel

Adjuvant, Neoadjuvant, or Primary Therapy

- Stage III
 - Intravenous (IV) paclitaxel and Intraperitoneal (IP) cisplatin and IP paclitaxel
- Stages II-IV
 - Carboplatin and paclitaxel (**Administered weekly or every 3 weeks**)

Initial Treatment for Metastatic or Recurrent Disease

- Platinum Sensitive*
 - Carboplatin
 - Carboplatin and gemcitabine (Gemzar)
 - Carboplatin and paclitaxel
 - Carboplatin and weekly paclitaxel
- Platinum Resistant
 - Bevacizumab monotherapy
 - Docetaxel (Taxotere)
 - Gemcitabine (Gemzar)
 - Liposomal doxorubicin (Doxil)
 - Paclitaxel (weekly)
 - Paclitaxel and bevacizumab

Maintenance Therapy

- After response to initial treatment for platinum-sensitive disease
 - Sensitive* to platinum-based therapies
 - Niraparib (Zejula)
 - Olaparib (Lynparza)
 - Rucaparib (Rubraca)

* Platinum sensitive disease is defined as recurrence of greater than 6 months after prior platinum-based therapy

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631

Last review: 8/8/2023 | Effective date: 10/16/2023

© 2023 Carelon Medical Benefits Management

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue
South Tower – Suite 800 Chicago, IL 60631

Last review: 8/8/2023 | Effective date: 10/16/2023

© 2023 Carelon Medical Benefits Management